Scientists use AI to find new antibiotic to fight superbug
Betsy Goodfellow | May 26, 2023 | News story | Research and Development | AI, Microbiology, WHO, abaucin, antibiotic resistance
Scientists at McMaster University and the Massachusetts Institute of Technology (MIT) have utilised artificial intelligence (AI) in order to discover a new antibiotic which, it appears, could be used to fight a drug-resistant ‘superbug’ which often circulates among vulnerable hospital patients.
The World Health Organization (WHO) has identified Acinetobacter baumannii as one of the world’s most dangerous anti-biotic resistant bacteria, which the researchers were attempting to treat.
Often, this bacterium is found in hospital settings, surviving on surfaces for long periods of time, as well as picking up DNA from other species of bacteria in its environment, for example antibiotic-resistant genes.
The study was published in Nature Chemical Biology and explains how the researchers utilised an AI platform to predict the structural classes of antibacterial molecules and ultimately identify a new antibacterial compound named abaucin.
Jonathan Stokes, lead author on the study and an assistant professor in McMaster University’s Department of Biomedicine and Biochemistry, commented: “This work validates the benefits of machine learning in the search for new antibiotics. Using AI, we can rapidly explore vast regions of chemical space, significantly increasing the chances of discovering fundamentally new antibacterial molecules. […] We know broad-spectrum antibiotics are suboptimal and that pathogens have the ability to evolve and adjust to every trick we throw at them. AI methods afford us the opportunity to vastly increase the rate at which we discover new antibiotics, and we can do it at a reduced cost. This is an important avenue of exploration for new antibiotic drugs.”
James J Collins, professor of medical engineering and science at MIT and Life Sciences faculty lead at the MIT Abdul Latif Jameel Clinic for Machine Learning in Health, added: “AI approaches to drug discovery are here to stay and will continue to be refined. We know algorithmic models work, now it’s a matter of widely adopting these methods to discover new antibiotics more efficiently and less expensively.”
Betsy Goodfellow
Related Content
Aiforia deal to expand access to pathology AI
Aiforia has signed a commercial agreement with PathAI to make its artificial intelligence (AI) solutions …
Cori Clinical raises US$4m to expand AI platform for clinical trial design
Cori Clinical has raised US$4m in a seed funding round to expand its AI platform …
Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster
By Chris Moore Commercial engagement in biopharma used to centre largely on direct conversations between …
